Detail
LncRNA Name | H19 |
Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
Region | GRCh38_11:1995176-2001470 Sequence |
Ensembl | ENSG00000130600 |
RefSeq | NR_002196 |
Circulating | ✘ |
Drug-resisitant | ✔ |
Prognostic | ✔ |
MiRNA | ✘ |
Variant | ✘ |
TF | ✘ |
Methylation | ✘ |
Cancer Name | lung adenocarcinoma |
ICD-0-3 | C34 M8140/3 |
Methods | qPCR, RNAi, Western blot, Flow cytometry assay etc. |
Sample | LUAD tissues, cell lines (A549, A549/DDP) |
Expression Pattern | up-regulated |
Function Description | In our study, the expression of H19 in cisplatin-resistant A549/DDP cells was unregulated. Knockdown of H19 restored the response of A549/DDP cells to cisplatin. H19-mediated chemosensitivity enhancement was associated with metastasis, induction of G0/G1 cell-cycle arrest, cell proliferation, and increased apoptosis. Furthermore, lncRNA H19 expression was significantly related to TNM stage and metastasis. Overexpression of H19 was negatively correlated with cisplatin-based chemotherapy response in patients. |
Pubmed ID | 27911863 |
Year | 2017 |
Title | Correlation of long non-coding RNA H19 expression with cisplatin-resistance and clinical outcome in lung adenocarcinoma. |
External Links |
Links for H19 | GenBank HGNC lncrnadb Noncode |
Links for lung adenocarcinoma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.